Questions have been renumbered as there were two question 3.
For the period April 1st to December 31st 2023, please provide the following information:
1. How many whole time equivalent histopathology consultants (as defined by being on the GMC specialist register for pathology) were employed by the authority at 31/12/2023.
2. How many histology cases were reported in the following period, overall and by the following sub-specialties
a. dermatology
b. gastro-intenstinal
c. urology
d. gynaecology
e. breast
f. thoracic
g. head and neck
h. other
i. total cases reported
3. How many of the total cases given above were reported by
a. consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs.
b. consultants employed by the authority, being paid additional amounts over and above their salary for additional work.
c. locum consultants working for the authority
d. external reporting companies.
4. Please provide a total number of cases and the number reported by each of the following:
i. Unilabs
ii. HCA Laboratories including their subsidiary Backlogs
iii. Source LD Path (previously Source Bioscience, and LD Path limited)
iv. Cellular Pathology Services Limited
v. Diagnexia
vi. Digital Pathology Partners
vii. Cyted (including their subsidiary Pathognomics)
viii. Poundbury Cancer Institute
ix. Medica
x. external reporting companies total
5. How much did the authority spend on each of the following during the period
a. consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs. (salary plus NI plus pension contribution)
b. consultants employed by the authority, being paid additional amounts over and above their salary for additional work.
c. locum consultants working for the authority
d. external reporting companies.
6. Please provide a total spend and the spend with each of the following:
i. Unilabs
ii. HCA Laboratories including their subsidiary Backlogs
iii. Source LD Path (previously Source Bioscience, and LD Path limited)
iv. Cellular Pathology Services Limited
v. Diagnexia
vi. Digital Pathology Partners
vii. Cyted (including their subsidiary Pathognomics)
viii. Poundbury Cancer Institute
ix. Medica
x. external reporting companies total
